Mirum Pharmaceuticals Q4 2023 Earnings Report

Mirum Pharmaceuticals EPS Results

• Actual EPS: -$0.66
• Consensus EPS: -$0.34
• Beat/Miss: Missed by -$0.32
• One Year Ago EPS: N/A

Mirum Pharmaceuticals Revenue Results

• Actual Revenue: $69.55 million
• Expected Revenue: $66.73 million
• Beat/Miss: Beat by +$2.82 million
• YoY Revenue Growth: N/A

Mirum Pharmaceuticals Announcement Details

• Quarter: Q4 2023
• Date: 2/28/2024
• Time: N/A

Mirum Pharmaceuticals (NASDAQ:MIRM), a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.